{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"73.1","upperLimit":"95.7","value":"89"},{"groupId":"OG001","lowerLimit":"28.7","upperLimit":"71.9","value":"52.6"},{"groupId":"OG002","lowerLimit":"68.6","upperLimit":"93.8","value":"85.6"},{"groupId":"OG003","lowerLimit":"33.4","upperLimit":"76.4","value":"58.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"37"},{"groupId":"OG003","value":"20"}],"units":"Participants"}],"description":"Analyzed by estimating the 2-year EFS of negative MRD and positive MRD by arm. Minimal disease was performed using serial assessments of the t(2;5)(p23;q35) NPM-ALK fusion transcript using quantitative RT-PCR. Quantitative RT-PCR was performed by extracting total RNA from peripheral blood specimens. Peripheral blood samples were obtained at baseline, on day 1 of cycle 1, and on day 1 of cycle 2. The normalized copy numbers (NCN) were expressed as copy numbers of NPM-ALK per 104 copies of ABL. Minimal disease (MDD) was defined as \\>10 NCN at baseline.","dispersionType":"95% Confidence Interval","groups":[{"description":"COURSE A (CYCLES 1, 3, AND 5): Patients receive brentuximab vedotin intravenously (IV) over 30 minutes on day 1, dexamethasone orally (PO) twice daily (BID) or IV on days 1-5, ifosfamide IV over 60 minutes on days 1-5, methotrexate IV over 3 hours on day 1, cytarabine IV over 1-30 minutes every 12 hours for 4 doses on days 4 and 5, and etoposide IV over 2 hours on days 4 and 5.\n\nCOURSE B (CYCLES 2, 4, AND 6): Patients receive brentuximab vedotin, dexamethasone, and methotrexate as in Arm BV, Course A. Patients also receive cyclophosphamide IV over 15-30 minutes on days 1-5 and doxorubicin hydrochloride IV over 1-15 minutes on days 4 and 5.","id":"OG000","title":"MRD Negative Arm BV (Brentuximab Vedotin, Combination Chemotherapy)"},{"description":"COURSE A (CYCLES 1, 3, AND 5): Patients receive brentuximab vedotin intravenously (IV) over 30 minutes on day 1, dexamethasone orally (PO) twice daily (BID) or IV on days 1-5, ifosfamide IV over 60 minutes on days 1-5, methotrexate IV over 3 hours on day 1, cytarabine IV over 1-30 minutes every 12 hours for 4 doses on days 4 and 5, and etoposide IV over 2 hours on days 4 and 5.\n\nCOURSE B (CYCLES 2, 4, AND 6): Patients receive brentuximab vedotin, dexamethasone, and methotrexate as in Arm BV, Course A. Patients also receive cyclophosphamide IV over 15-30 minutes on days 1-5 and doxorubicin hydrochloride IV over 1-15 minutes on days 4 and 5.","id":"OG001","title":"MRD Positive Arm BV (Brentuximab Vedotin, Combination Chemotherapy)"},{"description":"COURSE A (CYCLES 1, 3, AND 5): Patients receive crizotinib PO BID on days 1-21 and dexamethasone, ifosfamide, methotrexate, cytarabine, and etoposide as in Arm BV, Course A.\n\nCOURSE B (CYCLES 2, 4, AND 6): Patients receive crizotinib as in Arm CZ, Course A and dexamethasone, cyclophosphamide, methotrexate, and doxorubicin hydrochloride as in Arm BV, Course B.","id":"OG002","title":"MRD Negative Arm CZ (Crizotinib, Combination Chemotherapy)"},{"description":"COURSE A (CYCLES 1, 3, AND 5): Patients receive crizotinib PO BID on days 1-21 and dexamethasone, ifosfamide, methotrexate, cytarabine, and etoposide as in Arm BV, Course A.\n\nCOURSE B (CYCLES 2, 4, AND 6): Patients receive crizotinib as in Arm CZ, Course A and dexamethasone, cyclophosphamide, methotrexate, and doxorubicin hydrochloride as in Arm BV, Course B.","id":"OG003","title":"MRD Positive Arm CZ (Crizotinib, Combination Chemotherapy)"}],"paramType":"NUMBER","populationDescription":"11 Arm BV patients without adequate MDD baseline data, 1 Arm CZ patient who did not start treatment, and 11 Arm CZ patients without adequate MDD baseline data are excluded from these analyses.","reportingStatus":"POSTED","timeFrame":"Baseline up to progressive disease, relapse, or death, assessed up to 2 years","title":"Prognostic Significance of Minimal Residual Disease","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}